Indaptus Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Indaptus Therapeutics, Inc.'s free cash flow has decreased 20.29% from $-12.32M last year to $-14.82M, signaling decreasing performance

Indaptus Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Indaptus Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.02 last year to 0.00 today, signaling strengthened financials

Indaptus Therapeutics, Inc. has a net cash position, so leverage is healthy.

Indaptus Therapeutics, Inc. carries no debt; interest obligations are fully covered.

Indaptus Therapeutics, Inc. has insufficient data to evaluate this check.

Indaptus Therapeutics, Inc.'s short-term assets of $9.31M exceed its short-term liabilities of $6.16M

Indaptus Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Indaptus Therapeutics, Inc.'s return on equity of -1.03K%, is lower than 15.00%, indicating bad performance

Indaptus Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Indaptus Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Indaptus Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Indaptus Therapeutics, Inc. has negative free cash flow, indicating cash burn

Indaptus Therapeutics, Inc.'s yearly earnings has decreased 38.79% since last year from $-15.02M to $-20.85M, signaling decreasing performance

Indaptus Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -1.40K% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Indaptus Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Indaptus Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Indaptus Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Indaptus Therapeutics, Inc. has insufficient data to evaluate this check.

Indaptus Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Indaptus Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Indaptus Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Indaptus Therapeutics, Inc. has insufficient data to evaluate this check.

Indaptus Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Indaptus Therapeutics, Inc. has a price-to-book ratio of 2.07x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Indaptus Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue